Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment

被引:29
|
作者
Watson, Bianca
Conigrave, Katherine M.
Wallace, Cate
Whitfield, John B.
Wurst, Friedrich
Haber, Paul S.
机构
[1] Royal Prince Alfred Hosp, Drug Hlth Serv, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
[3] Univ Sydney, Discipline Med, Sydney, NSW 2006, Australia
[4] Univ Basel, Psychiat Clin, CH-4003 Basel, Switzerland
关键词
alcohol; buprenorphine; hepatitis B; hepatitis C; methadone; opioid dependence;
D O I
10.1080/09595230701247681
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Amongst people on opioid maintenance treatment (OMT), chronic hepatitis C (HCV) is common but infrequently treated. Numerous barriers, including misuse of alcohol may limit efforts at anti-viral treatment. The aim of this study was to define barriers, including alcohol misuse, to the effective treatment of HCV amongst OMT recipients. Ninety-four OMT patients completed the 3-item Alcohol Use Disorders Identification Test (AUDIT-C). A semi-structured interview was used in 53 subjects to assess alcohol use in detail, psychological health, discrimination and access to HCV treatment. Feasibility of brief intervention for alcohol misuse was assessed. Of the screening participants, 73% reported they were HCV positive. Of the detailed interview participants, 26% reported no drinking in the past month, but 53% scored 8 or more on AUDIT and 42% exceeded NHMRC drinking guidelines. Twenty subjects received brief intervention and among 17 re-interviewed at one month, alcohol consumption fell by 3.1 g/day (p = 0.003). Severe or extremely severe depression, stress and anxiety were found in 57%, 51% and 40% of interviewees respectively. Episodic heavy drinking, mental health problems, perceived discrimination, limited knowledge concerning HCV were all common and uptake of HCV treatment was poor. Brief intervention for alcohol use problems was acceptable to OMT patients, and warrants further study.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 50 条
  • [21] Medication Adherence Among Patients With Chronic Hepatitis Receiving Antiviral Treatment
    Go, Hirofumi
    Tanaka, Makoto
    Yamamoto-Mitani, Noriko
    Suzuki, Miho
    Kawakami, Aki
    Masaki, Naohiko
    Shimada, Megumi
    GASTROENTEROLOGY NURSING, 2019, 42 (02) : 140 - 149
  • [22] Perceived barriers to methadone maintenance treatment among Iranian opioid users
    Maryam Khazaee-Pool
    Maryam Moeeni
    Koen Ponnet
    Arezoo Fallahi
    Leila Jahangiri
    Tahereh Pashaei
    International Journal for Equity in Health, 17
  • [23] Perceived barriers to methadone maintenance treatment among Iranian opioid users
    Khazaee-Pool, Maryam
    Moeeni, Maryam
    Ponnet, Koen
    Fallahi, Arezoo
    Jahangiri, Leila
    Pashaei, Tahereh
    INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2018, 17
  • [24] Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England
    Hibbert, Matthew
    Simmons, Ruth
    Harris, Helen
    Desai, Monica
    Sabin, Caroline A. A.
    Mandal, Sema
    JOURNAL OF VIRAL HEPATITIS, 2023, 30 (08) : 646 - 655
  • [25] HEPATITIS C MANAGEMENT AMONG PATIENTS RECEIVING OPIOID SUBSTITUTION TREATMENT IN GENERAL PRACTICE IN IRELAND
    Murtagh, R.
    Swan, D.
    O'Connor, E.
    McCombe, G.
    Murphy, C.
    Lambert, J. S.
    Avramovic, G.
    Cullen, W.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S466 - S466
  • [26] Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study
    Artenie, Andreea A.
    Cunningham, Evan B.
    Dore, Gregory J.
    Conway, Brian
    Dalgard, Olav
    Powis, Jeff
    Bruggmann, Philip
    Hellard, Margaret
    Cooper, Curtis
    Read, Philip
    Feld, Jordan J.
    Hajarizadeh, Behzad
    Amin, Janaki
    Lacombe, Karine
    Stedman, Catherine
    Litwin, Alain H.
    Marks, Pip
    Matthews, Gail, V
    Quiene, Sophie
    Erratt, Amanda
    Bruneau, Julie
    Grebely, Jason
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (11) : 2369 - 2376
  • [27] Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
    Christer F. Aas
    Jørn Henrik Vold
    Svetlana Skurtveit
    Ingvild Odsbu
    Fatemeh Chalabianloo
    Aaron G. Lim
    Kjell Arne Johansson
    Lars Thore Fadnes
    Substance Abuse Treatment, Prevention, and Policy, 15
  • [28] Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
    Aas, Christer F.
    Vold, Jorn Henrik
    Skurtveit, Svetlana
    Odsbu, Ingvild
    Chalabianloo, Fatemeh
    Lim, Aaron G.
    Johansson, Kjell Arne
    Fadnes, Lars Thore
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2020, 15 (01)
  • [29] Feasibility of alcohol screening among patients receiving opioid treatment in primary care
    Anne Marie Henihan
    Geoff McCombe
    Jan Klimas
    Davina Swan
    Dorothy Leahy
    Rolande Anderson
    Gerard Bury
    Colum P. Dunne
    Eamon Keenan
    John S. Lambert
    David Meagher
    Clodagh O’Gorman
    Tom P. O’Toole
    Jean Saunders
    Gillian W. Shorter
    Bobby P. Smyth
    Eileen Kaner
    Walter Cullen
    BMC Family Practice, 17
  • [30] Feasibility of alcohol screening among patients receiving opioid treatment in primary care
    Henihan, Anne Marie
    McCombe, Geoff
    Klimas, Jan
    Swan, Davina
    Leahy, Dorothy
    Anderson, Rolande
    Bury, Gerard
    Dunne, Colum P.
    Keenan, Eamon
    Lambert, John S.
    Meagher, David
    O'Gorman, Clodagh
    O'Toole, Tom P.
    Saunders, Jean
    Shorter, Gillian W.
    Smyth, Bobby P.
    Kaner, Eileen
    Cullen, Walter
    BMC FAMILY PRACTICE, 2016, 17 : 1 - 10